ResusX:Podcast

In this episode, we tackle one of the most persistent questions in perioperative care: how low is too low when it comes to hemoglobin in high-risk cardiac patients after major surgery? The long-standing restrictive threshold of 7 g/dL has been considered safe for years, but the TOP Trial challenges that comfort zone. More than 1,400 high-risk veterans were randomized to either a liberal transfusion strategy (Hgb <10 g/dL) or a restrictive one (Hgb <7 g/dL). The primary outcome showed no significant difference in death or major ischemic events. That part was expected. The surprise came in the secondary outcomes. Patients in the restrictive group had nearly double the rate of non-fatal cardiac complications, including new heart failure and dangerous arrhythmias. The liberal strategy cut those complications by almost 40 percent. This episode breaks down what these findings mean for real-world practice, how they challenge current transfusion guidelines, and when you might reconsider your trigger for your most vulnerable post-op patients. If you take care of surgical patients with cardiac risk, this is an episode you cannot skip.

For decades, we’ve been told vasopressors belong only through central lines — but what if that’s not the whole story? In this episode, we unpack a groundbreaking multicenter study from Addis Ababa that dares to challenge convention. Researchers followed 250 patients in shock, tracking survival outcomes, complications, and safety when vasopressors were given peripherally instead of through central access. The result? A strikingly low extravasation rate of just 1.2%, with all complications occurring only after five days of infusion. For short-term management, the data suggests — peripheral might be not only feasible, but safe. We’ll explore what this means for critical care teams everywhere — especially in resource-limited settings where central access isn’t always an option. Is it time to rewrite the playbook for shock management? What are the risks, the predictors of survival, and the real-world tradeoffs? Tune in as we dig into the data, the debates, and the bedside lessons from this landmark study — and ask the question every critical care clinician should be thinking about: Are we overcomplicating vasopressor delivery? Science meets practicality. Evidence meets the frontline. And the future of shock resuscitation might just look a little different.

Are we giving our older patients with out-of-hospital cardiac arrest (OHCA) a fair shot? ⏱️ Current guidelines say an ECPR initiation time of up to 60 minutes is acceptable, but is that really the case for everyone? This is a question clinicians grapple with every day at the bedside. A new nationwide observational study from South Korea tackles this head-on, analyzing data from 483 adult patients who received ECPR for non-traumatic OHCA. The study found that while both age and time to ECPR independently predict survival, the combination of the two is critical. The key takeaway? The "golden hour" for ECPR may not apply to our elderly patients. The results are practice-changing and frankly, a wake-up call. The study found that in patients over 65, the probability of survival plummeted to less than 10% when ECPR was delayed beyond just 21 minutes. For their younger counterparts, a 10% survival rate was maintained for nearly twice as long, up to 38 minutes    . This finding suggests that for older patients, the effective window for ECPR is much shorter than previously thought . The authors recommend a sense of urgency, urging clinicians to activate ECPR in carefully selected elderly patients almost immediately upon hospital arrival    .  This isn't just about a new number; it's about re-evaluating our clinical protocols and embracing an age-specific approach to resuscitation. Tune in as we break down the data and discuss what this means for your next OHCA case.

When a patient crashes with acute cardiogenic pulmonary edema, emergency teams need fast, effective solutions. For years, non-invasive ventilation (NIV) has been the gold standard — but could high-flow nasal cannula (HFNC) be just as good? In this episode, we break down a prospective, randomized trial published in the American Journal of Emergency Medicine (Dec 2025) that compared HFNC head-to-head with NIV in the ED. The results? No difference in survival, respiratory rates, or dyspnea scores between the two therapies. We’ll explore: Why HFNC may rival NIV for managing ACPE The surprising equivalence in clinical outcomes at 30, 60, and 120 minutes Patient comfort and tolerability — where HFNC may hold the edge What this means for ED practice, protocols, and future airway management If you’re an emergency physician, intensivist, or resuscitationist, this study has big implications: it suggests you may have more flexibility — and your patients, more comfort — than ever before.

When major abdominal surgery pushes patients to the brink, timing is everything, especially with norepinephrine. Could giving it earlier to high-risk patients prevent dangerous drops in blood pressure and reduce complications? A new randomized controlled trial, published in Anesthesiology (2025), put this to the test, comparing early, low-dose norepinephrine infusion against standard care in high-risk surgical patients. The results may surprise you: early norepinephrine not only stabilized blood pressure faster but also significantly reduced postoperative complications without increasing adverse events. In this episode, we break down what “early” really means, why the trial’s pragmatic design matters, and how this could reshape perioperative hemodynamic management in major surgery. Key takeaways: • Early norepinephrine led to more stable intraoperative blood pressure • Reduced risk of postoperative complications in high-risk patients • No significant increase in adverse events compared to standard care This isn’t just about drugs, it’s about redefining timing in critical surgical care. Want to dig deeper? Check out the full study: Trocheris-Fumery O, Flet T, Scetbon C, et al. Early Use of Norepinephrine in High-Risk Patients Undergoing Major Abdominal Surgery: A Randomized Controlled Trial. Anesthesiology. 2025. doi:10.1097/ALN.0000000000005704

Can IV vitamin C really save lives in the PICU? It’s been a hot topic in critical care circles for years—but the VITACIPS trial just delivered a powerful dose of clarity. In this episode, we dive into the results of this rigorous study and what they mean for treating children in septic shock. Spoiler: it’s not the magic bullet many hoped for. We break down key findings, clinical implications, and why this trial is a turning point in how we think about adjunct therapies in pediatrics. Whether you're treating pediatric patients or just curious about how cutting-edge research shapes real-world care, this one’s worth the listen. Based on the article: “Vitamin C Versus Placebo in Pediatric Septic Shock (VITACIPS) – A Randomised Controlled Trial” by Jhuma Sankar et al., Journal of Intensive Care Medicine.

When seconds count and precision matters—like during surgery—getting accurate, continuous blood pressure readings is critical. That’s where radial artery cannulation comes in. But while traditional methods rely on “feeling the pulse,” they’re not always reliable, especially in tough cases. Enter a game-changing technique: ultrasound-guided Dynamic Needle Tip Positioning (DNTP). In this episode, we dive into a powerful new study that compares old-school palpation to DNTP and the results are stunning: an 88.5% first-pass success rate, fewer attempts, less time, and reduced equipment use with the ultrasound approach. We explore why this matters for patient safety, comfort, and clinical efficiency—and how this could redefine arterial cannulation in the OR. Could this be the new gold standard for arterial access? Tune in and find out. Read the full study: "Palpation versus Ultrasound-Guided Dynamic Needle Tip Positioning Technique for Radial Artery Cannulation" by Sujan Dhakal et al. in Annals of Cardiac Anaesthesia.

When seconds count in the ICU, the IV fluid you choose could literally make or break a patient’s recovery. In this episode, we’re unpacking one of the biggest debates in critical care: balanced crystalloids vs. normal saline. A massive new meta-analysis of over 35,000 patients drops a game-changing truth—your fluid choice must depend on whether the patient has a traumatic brain injury (TBI). Balanced solutions may lower mortality in most critically ill patients, but for those with TBI, they could actually do harm. Tune in to hear how this data is flipping standard practice on its head and pushing the ICU world toward smarter, personalized resuscitation. Want to dive deeper? Check out the full study “Effect of Treatment With Balanced Crystalloids Versus Normal Saline on the Mortality of Critically Ill Patients With and Without Traumatic Brain Injury” by José C. Diz et al. in Critical Care and Resuscitation.